Lopez-Navarro, Edgar R.
Delfs, Christofer
Jarre, Andrea
Sanio, Vivian
Greif, Götz
Gutierrez, Jose
Ringelstein, E. Bernd
Meuth, Sven G.
Haensch, Carl-Albrecht
Ringelstein, Adrian
Ringelstein, Marius
Article History
Received: 18 January 2022
Accepted: 21 February 2022
First Online: 16 March 2022
Conflict of interest
: E.R. Lopez-Navarro, C. Delfs, A. Jarre, V. Sanio, G. Greif, E.B. Ringelstein, C.-A. Haensch and A. Ringelstein declare that they have no competing interests. J. Gutierrez declares no conflict of interest related to this work but NIH grants unrelated to this work. S.G. Meuth received speaker honoraria and travel reimbursement from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS and Teva, none related to this study. His research is supported by Bundesministerium für Bildung und Forschung (BMBF), Deutsche Forschungsgesellschaft (DFG), Else-Kröner-Fresenius-Stiftung, Deutscher Akademischer Austauschdienst, Hertie Stiftung, Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Münster, Deutsche Stiftung Neurologie and Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, und Teva, none related to this study. M. Ringelstein received speaker honoraria from Novartis, Bayer, Roche, Alexion and Ipsen and travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Grifols, Roche and Merck, none related to this study.